The Japanese medicines regulator has approved Tokyo-based Takeda Pharmaceutical’s (TSE: 4502) application to market Entyvio (vedolizumab) in ulcerative colitis (UC).
The application, which was based on results from the Phase III CCT-101 and GEMINI 1 studies, was filed with the Ministry of Health, Labor and Welfare (MHLW) in August last year.
The approval in Takeda’s home country comes after European Union and US approvals in May 2014, where the therapy has been used to treat patients with UC or Crohn’s disease for whom conventional therapy or a TNFα blocker has not worked.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze